• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,550.25 918.60
( 1.20%)
Global Indices
Nasdaq
47,930.49 -276.32
(-0.57%)
Dow Jones
6,837.38 -8.28
(-0.12%)
Hang Seng
56,916.27 1,020.95
(1.83%)
Nikkei 225
10,596.33 -7.15
(-0.07%)
Forex
USD-INR
92.50 0.06
(0.07%)
EUR-INR
108.05 0.09
(0.08%)
GBP-INR
124.08 0.03
(0.03%)
JPY-INR
0.58 0.00
(-0.25%)

EQUITY - MARKET SCREENER

Mangalam Drugs and Organics Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532637
INE584F01014
80.5027493
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MANGALAM
0
48.37
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

K&R Rail Engineering slumps after dismal Q2 performance
Nov 13,2025
Revenue from operations fell 79.05% year-on-year (YoY) to Rs 33.77 crore in the quarter ended 30 September 2025.

The company reported loss before tax stood at Rs 0.39 crore in Q2 FY26 as against a profit of Rs 7.58 crore in the same period last year.

Total expenses tumbled 77.85% YoY to Rs 34.23 crore in Q2 FY26. Employee benefits expenses stood at Rs 0.47 crore (down 49.46%), while finance costs were at Rs 0.42 crore (up 10.53% YoY) during the period under review.

On a half-year basis, the company’s net profit tumbled 96.31% to Rs 0.30 crore on a 59.85% rise in revenue from operations to Rs 121.83 crore in H1 FY26 over H1 FY25.

K&R Rail Engineering is carrying on the business of providing end-to-end EPCC services, which include earthwork, bridges & civil works, track works, overhead electrification (OHE) works, signaling & telecommunication (S&T) works, railway operation & maintenance (O&M) consultancy in preparing detailed DPRs, and other allied activities.